Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ViatrisXSWX:VTRS +0.99%60 5-Year Yield-on-Cost % is 1.36 as of Jul. 19, 2026, which is 68% below its 10-year median of 4.22. GuruFocus rates XSWX:VTRS with a GF Score™ of 60/100 and a GF Value™ of CHF8.94. The stock has 8 warning signs investors should review. Among 513 Drug Manufacturers companies, Viatris ranks better than 54.78% on this metric.
Viatris's yield on cost for the quarter that ended in Mar. 2026 was 1.36.
The historical rank and industry rank for Viatris's 5-Year Yield-on-Cost % or its related term are showing as below:
XSWX:VTRS'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.74 Med: 4.22 Max: 6.37
Current: 1.36
During the past 13 years, Viatris's highest Yield on Cost was 6.37. The lowest was 0.74. And the median was 4.22.
XSWX:VTRS's 5-Year Yield-on-Cost % is ranked better than 54.78% of 513
companies
in the Drug Manufacturers industry
Industry Median: 2.29
vs XSWX:VTRS: 1.36
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Viatris 5-Year Yield-on-Cost % Related Terms
XSWX:VTRS vs NBIX, UTHR, ELAN: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Viatris's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Viatris is calculated as
Viatris (XSWX:VTRS) has a 5-Year Yield-on-Cost % of 1.36 as of Jul. 19, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Viatris and its competitors. This is 68% below median its historical median of 4.22. Over the past decade, Viatris' 5-Year Yield-on-Cost % has ranged from 0.74 to 6.37. According to the industry distribution chart, Viatris ranks #232 out of 513 companies in the Drug Manufacturers industry, placing it in the top 45.2%.
Is Viatris' 5-Year Yield-on-Cost % too high?
Viatris' current 5-Year Yield-on-Cost % of 1.36 is 68% below median its 10-year median of 4.22. Over the past 10 years, this metric has ranged from a low of 0.74 to a high of 6.37. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.29. Viatris' value of 1.36 is 40.6% below this industry median. Based on the distribution chart, Viatris ranks #232 out of 513 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Viatris has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Viatris' 5-Year Yield-on-Cost % compare to NBIX and UTHR?
According to the Drug Manufacturers industry distribution chart, Viatris ranks #232 out of 513 companies for 5-Year Yield-on-Cost %. This puts Viatris in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.29. Viatris' value of 1.36 is 40.6% below this benchmark. Historically, Viatris' own 5-Year Yield-on-Cost % has ranged from 0.74 to 6.37 over the past decade. While the company's 10-year median is 4.22 vs. the industry median of 2.29, Viatris has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.29, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viatris's current 5-Year Yield-on-Cost % of 1.36 is 40.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Viatris and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viatris's current 5-Year Yield-on-Cost % is 1.36, which is 68% below median its own 10-year median of 4.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Viatris (XSWX:VTRS) has a current 5-Year Yield-on-Cost % of 1.36. The stock's GF Value™ is CHF8.94, compared to a current price of CHF14.03 — trading 57% above its estimated fair value. The current 5-Year Yield-on-Cost % is 1.36, which is 68% below median its 10-year median of 4.22 and 40.6% below the Drug Manufacturers industry median of 2.29. Viatris' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Viatris (XSWX:VTRS), the current 5-Year Yield-on-Cost % is 1.36 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viatris (XSWX:VTRS) Overvalued in 2026?
Based on GuruFocus' analysis, Viatris stock appears to be overvalued.
The current stock price of CHF14.03 is trading 57% above its estimated GF Value™ of CHF8.94.
Key valuation signals for XSWX:VTRS:
5-Year Yield-on-Cost %: 1.36 (68% below median its 10-year median of 4.22)
GF Value™: CHF8.94 vs. price of CHF14.03 (57% above fair value)
Industry Position: 40.6% below the Drug Manufacturers median (#232 of 513)
No single metric tells the full story. See the XSWX:VTRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
60GF Score
Get the complete analysis for XSWX:VTRS
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:VTRS has been successfully added to your 
